Noncoding RNAs in prostate cancer: The long and the short of it CME

Clinical Cancer Research

Volumn 20, Issue 1, 2014, Pages 35-43

  Bolton, Eva M ^a,b   Tuzova, Alexandra V ^a   Walsh, Anna L ^a,b   Lynch, Thomas ^b   Perry, Antoinette S ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LONG UNTRANSLATED RNA; MICRORNA; PIWI INTERACTING RNA; REGULATORY RNA; RIBONUCLEASE P; RIBOSOME RNA; SMALL NUCLEAR RNA; SMALL UNTRANSLATED RNA; TELOMERASE RNA; TRANSFER RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; GENETIC LINKAGE; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA SYNTHESIS; RNA TRANSLATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; MALE; MUTATION; PROGNOSIS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, UNTRANSLATED; TUMOR MARKERS, BIOLOGICAL;

EID: 84892154925     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1989     Document Type: Review

References (75)

1. Consortium EP, Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007;447:799-816.
2. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 2007;316:1484-8.
3. Metzker ML. Sequencing technologies-the next generation. Nat Rev Genet 2010;11:31-46.
4. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92.
5. Kozomara A, Griffiths-Jones S. miR Base: integrating micro RNA annotation and deep-sequencing data. Nucleic Acids Res 2011;39:D152-7.
6. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalianm RNAs are conserved targets of micro RNAs. Genome Res 2009;19:92-105.
7. Iorio MV, Croce CM. micro RNA involvement in human cancer. Carcinogenesis 2012;33:1126-33.
8. Fabian MR, Sonenberg N. The mechanics of mi RNA-mediated gene silencing: a look under the hood of mi RISC. Nat Struct Mol Biol 2012;19:586-93.
9. O'Kelly F, Marignol L, Meunier A, Lynch TH, Perry AS, Hollywood D. Micro RNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol 2012;9:397-407.
10. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. Micro RNA expression profiling in prostate cancer. Cancer Res 2007;67:6130-5.
11. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of micro RNA expression in human prostate cancer. Oncogene 2008;27:1788-93.
12. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of micro RNA and messenger RNA reveals deregulated micro RNA expression in prostate cancer. Cancer Res 2008; 68:6162-70.
13. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, et al. Micro RNA profile analysis of human prostate cancers. Cancer Gene Ther 2009; 16:206-16.
14. Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S, et al. The micro RNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 2010;8:529-38.
15. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, Trapman J, et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2012; 31:978-91.
16. Liu C, Kelnar K, Vlassov AV, Brown D, Wang J, Tang DG. Distinct micro RNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res 2012;72:3393-404.
17. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009;138:245-56.
18. Ostling P, Leivonen SK, Aakula A, Kohonen P, Makela R, Hagman Z, et al. Systematic analysis of micro RNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 2011;71:1956-67.
19. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010;17:193-9.
20. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Differential regulation of micro RNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007;6:1586-93.
21. Hagman Z, Larne O, Edsjo A, Bjartell A, Ehrnstrom RA, Ulmert D, et al. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 2010;127:2768-76.
22. Yamamura S, Saini S, Majid S, Hirata H, Ueno K, Deng G, et al. MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One 2012;7: e29722.
23. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The micro RNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011;17:211-5.
24. Hulf T, Sibbritt T, Wiklund ED, Patterson K, Song JZ, Stirzaker C, et al. Epigenetic-induced repression of micro RNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene 2013;32:2891-9.
25. Boll K, Reiche K, Kasack K, Morbt N, Kretzschmar AK, Tomm JM, et al. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 2013;32:277-85.
26. Hagman Z, Haflidadottir BS, Ceder JA, Larne O, Bjartell A, Lilja H, et al. miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer 2013;108:1668-76.
27. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593-601.
28. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009;69:2287-95.
29. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, et al. Loss of p63 and its micr oR NA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A 2012;109:15312-7.
30. Gandellini P, Profumo V, Casamichele A, Fenderico N, Borrelli S, Petrovich G, et al. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ 2012;19:1750-60.
31. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008;14:1271-7.
32. Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 2009;69:3356-63.
33. Sun T, Yang M, Chen S, Balk S, Pomerantz M, Hsieh CL, et al. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate 2012;72:1093-103.
34. Sun T, Wang X, He HH, Sweeney CJ, Liu SX, Brown M, et al. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene 2013. [Epub ahead of print]
35. Dong XY, Rodriguez C, Guo P, Sun X, Talbot JT, Zhou W, et al. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet 2008;17:1031-42.
36. Lee JT. Epigenetic regulation by long noncoding RNAs. Science 2012;338:1435-9.
37. Moran VA, Perera RJ, Khalil AM. Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res 2012;40:6391-400.
38. Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol 2013;20:300-7.
39. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010;329:689-93.
40. Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L, et al. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci U S A 2000;97:12216-21.
41. Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 2004;23:605-11.
42. Fu X, Ravindranath L, Tran N, Petrovics G, Srivastava S. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol 2006;25:135-41.
43. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011;29:742-9.
44. Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009;41:1058-60.
45. Chung S, Nakagawa H, Uemura M, Piao L, Ashikawa K, Hosono N, et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci 2011;102:245-52.
46. Meyer LR, Zweig AS, Hinrichs AS, Karolchik D, Kuhn RM, Wong M, et al. The UCSC Genome Browser database: extensions and updates 2013. Nucleic Acids Res 2013;41:D64-9.
47. Jin G, Sun J, Isaacs SD, Wiley KE, Kim ST, Chu LW, et al. Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. Carcinogenesis 2011;32:1655-9.
48. Ren S, Peng Z, Mao JH, Yu Y, Yin C, Gao X, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res 2012;22:806-21.
49. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010;38:662-74.
50. Kondo Y, Koga S, Komata T, Kondo S. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene 2000;19:2205-11.
51. Folini M, Brambilla C, Villa R, Gandellini P, Vignati S, Paduano F, et al. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur J Cancer 2005;41:624-34.
52. Edwards J, Krishna NS, Witton CJ, Bartlett JM. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 2003;9:5271-81.
53. Bettendorf O, Heine B, Kneif S, Eltze E, Semjonow A, Herbst H, et al. Expression-patterns of the RNA component (hTR)and the catalytic subunit (hTERT) of human telomerase in nonneoplastic prostate tissue, prostatic intraepithelial neoplasia, and prostate cancer. Prostate 2003;55:99-104.
54. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
55. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
56. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59:5975-9.
57. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009;6:255-61.
58. Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H, et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011;59:96-105.
59. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010;70:10-6.
60. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
61. Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2012. [Epub ahead of print]
62. Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 2013;19:2442-50.
63. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova- Agadjanyan EL, et al. Circulating micro RNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
64. Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, et al. Expression differences of circulating micro RNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 2013;73:346-54.
65. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, et al. Serum mi RNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011;71:326-31.
66. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, et al. Circulating mi RNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011;128:608-16.
67. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, et al. Dysregulation of circulating micro RNAs and prediction of aggressive prostate cancer. Prostate 2012;72:1469-77.
68. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating micro RNA levels associated with prostate cancer. Br J Cancer 2012;106:768-74.
69. McNamara JO 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, et al. Cell type-specific delivery of si RNAs with aptamersi RNA chimeras. Nat Biotechnol 2006;24:1005-15.
70. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol 2012;13:e249-58.
71. Melo SA, Kalluri R. Molecular pathways: micro RNAs as cancer therapeutics. Clin Cancer Res 2012;18:4234-9.
72. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010;18:181-7.
73. Xu T, Xu Y, Liao CP, Lau R, Goldkorn A. Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo. Mol Cancer Ther 2010;9:438-49.
74. Xu T, He K, Wang L, Goldkorn A. Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference. Prostate 2011;71:1390-400.
75. Kannan K, Wang L, Wang J, Ittmann MM, Li W, Yen L. Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci U S A 2011;108:9172-7.